Effect of dexamethasone intravitreal implant (Ozurdex®) on corneal endothelium in retinal vein occlusion patients

BMC Ophthalmology

Table 2 ECD, CV, Hex and CCT values of injected and uninjected eyes before intravitreal injection and follow-up visits

		Before injection	1st month	3rd month	p value*
CD	Injected eyes	2211.7 ± 370.6	2207.1 ± 351.9	2163.8 ± 357.7^ab	0.018
CD	Uninjected eyes	2219.8 ± 263.2	2265.9 ± 254.2	2102.8 ± 551.9	0.179
CV	Injected eyes	37.86 ± 5.55	40.14 ± 6.47	40.05 ± 5.22	0.511
CV	Uninjected eyes	40.70 ± 8.46	41.35 ± 5.85	41.94 ± 9.22	0.842
Hex	Injected eyes	54.86 ± 6.84	55.81 ± 7.32	56.63 ± 8.25	0.481
Hex	Uninjected eyes	53.70 ± 8.55	53.95 ± 7.52	53.72 ± 8.92	0.879
CCT	Injected eyes	567.5 ± 43.0	564.1 ± 43.9	556.5 ± 44.3	0.810
CCT	Uninjected eyes	556.9 ± 35.2	558.8 ± 39.7	563.3 ± 41.2	0.104

*Friedman Test, aPost-hoc: Statistical difference detected before intravitreal injection and third month (p = 0.013), bPost-hoc: Statistical difference detected between first and third month (p = 0.009), ECD Endothelial cell density, CV Coefficient of variation of cell size, HEX Percentage of hexogonality and CCT Central corneal thickness by corneal specular microscopy

ISSN: 1471-2415